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An extensive literature relating patients’ expectations to treatment outcomes has not addressed 
the determinants of these expectations.  We argue that treatment history is part of a reference 
point that influences patients’ expectations of how effective further treatment might be, thus 
influencing whether to proceed with additional treatment or not.  We hypothesize that those 
patients with unsuccessful prior treatments have diminished expected improvement from 
subsequent treatments.  Prospect theory provides a theoretical foundation for reference frame 
effects, and the model is tested with data on patients diagnosed with idiopathic intracranial 
hypertension.  Our results support the reference frame hypothesis.   
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Introduction 
For some illnesses or health disorders, treatments are palliative rather than curative.  One 
commonly used measure of treatment effectiveness when conditions are without clear objective 
symptoms is self-reported changes in disease status.  Prior experience with, and earlier treatment 
for, the condition contributes to a frame of reference that may affect a patient’s perception of 
how much further treatment will improve his or her
1 health status.  More specifically, by 
affecting patients’ expectations about how effective a treatment might be, this reference point 
influences whether a patient pursues an additional treatment, as well as subsequent perceptions 
of how effective that treatment is.  Although there is an extensive literature on how patient 
expectations influence treatment outcome(s) and recovery speed, to our knowledge no existing 
research tests how prior treatment impacts reference point effects.  The purpose of this paper is 
to explore how reference points affect the perceived effectiveness of medical treatments. 
  The literature regarding the relationship between expectations and health is extensive, but 
many of these studies focus only on the fact that a connection exists, and not on the causal 
relationship (Carver et al., 1994; Frey et al., 1985; Koller et al., 2000).
 2  For example, Miceli and 
Castelfranchi (2002) speculate on the psychological effects of combining forecasts of future 
events with hopes and fears, both before and after the event occurs. 
  Another line of research finds that positive expectations speed recovery (Scheier, 1989 
and Scheier and Carver, 1987 for coronary bypass surgery; Frey et al., 1985 for recovery from 
accidents; and Kalauokalani et al., 2001, for low back pain).  Others find that positive 
expectations improve patients’ perceptions of subjective health (Carver et al., 1994 for breast 
                                                 
1 The data include both male and female patients.  For convenience only the female pronoun is used in the remainder 
of this paper. 
2 For summaries of the earlier literature see Ditto and Hilton (1990), Jones (1982), and Jones (1990).  3 
cancer patients; Llewellyn-Thomas, Thiel, and McGreal, 1992 for the general assessment of 
one’s own health; and Koller et al., 2000 for the quality of life of cancer patients). 
  None of these studies, however, address what determines expectations of treatment 
outcomes.  We argue that prior treatment provides a frame of reference which, along with other 
personal characteristics, affects patients’ baseline expectations of treatment success, which in 
turn influences their perceived effectiveness of that treatment.  We expect that patients with 
unsuccessful prior treatments have a frame of reference leaving them less likely to expect 
improvement from subsequent treatments.  We use Prospect Theory (Kahneman and Tversky, 
1979) to model frame of reference effects on subsequent treatment and expectations of 
effectiveness.  We test the implications of the model using the Monotone Rank Estimator (MRE) 
(Cavanagh and Sherman, 1998) with data on patients diagnosed with idiopathic intracranial 
hypertension (IIH).
3  The results support the proposition that prior treatment failure or success 
impacts a patient’s reference point, which in turn influences her perceptions about the 
effectiveness of subsequent treatments. 
  The remainder of this paper is organized into five sections.  In the next section we 
describe our model of treatment choice.  Successive sections discuss an application, our 
empirical methods and estimation results.  We finish the paper with conclusions and implications 
for future research. 
 
Frame of Reference and Treatment Choice 
Prospect theory (PT) was introduced as an alternative to expected utility theory (Von Neumann 
and Morgenstern, 2004) for modeling decisions under risk when those decisions are dependent 
                                                 
3 See Appendix A for a detailed explanation of this disorder. 
 4 
on a frame of reference.
4  Unlike expected utility theory where values are placed on final states, 
PT assumes that individuals assign values to gains and losses relative to a reference point.  The 
frame of reference can in principle influence the valuation of possible outcomes, the subjective 
probabilities of treatment effectiveness, and risk preferences.  In our model we focus on how a 
patient’s reference point affects her expectations of treatment success, thus determining the path 
of treatment, and, for subjective outcomes, the perceived success of treatments after the 
treatments have been pursued. 
  The value of a given prospect is measured by  
), ( ) ( ) ( ) ( ) , ; , ( y v q x v p q y p x V π π + =                 (1) 
where x and y are potential outcomes that occur with probabilities p and q, respectively.  The 
decision weights,  ) (⋅ π , measure not only the impact of the perceived (as opposed to actual) 
probabilities on the overall valuation of the prospect, but also the influence of factors such as 
ambiguity.  Kahneman and Tversky (1979) argue that in most cases  p p < ) ( π , and 
1 ) 1 ( ) ( < − + p p π π , but that small probabilities tend to be overweighted so that  p p > ) ( π  if p is 
small. 
The value function  ) (⋅ v measures the value of gains and losses relative to the reference 
point.  This function is believed to be concave for gains and convex for losses, giving it an S-
shape, as illustrated in Figure 1.  Consistent with the literature (Kahneman and Tversky, 1979), 
we assume that the function passes through the reference point, and is steeper for losses than 
gains, reflecting risk aversion.  The overweighting of low probability events and the 
                                                 
4 A revised version titled “cumulative prospect theory” (Tversky and Kahneman, 1992; Wakker and Tversky, 1993), 
applies to uncertain and risky prospects with multiple outcomes.  Under the extended theory decision weights are 
applied to cumulative, as opposed to individual, probabilities.  However, the extension gives the same results as the 
original theory for all two-outcome and mixed three-outcome prospects.  This paper focuses on three-outcome 
prospects, hence the earlier version of Prospect Theory (Kahneman and Tversky, 1979) is sufficient for our 
purposes. 5 
underweighting of high probability events is what can cause some people to be risk seeking for 
potential losses and risk averse for potential gains. 
  Many of the PT applications in health care focus on the effects of information framing on 
medical decisions (McNeil et al., 1988).  Meyerowitz and Chaiken (1987) find that the use of 
negatively framed information leads to increased breast self-examination.  Rothman et al. (1993) 
further corroborate the importance of framing by demonstrating that negative framing may be 
more effective in encouraging behaviors that are seen as risky (for example being tested for a 
sexually transmitted disease), while positive framing may be more effective in encouraging 
preventive behavior (for example, practicing safe sex).  Block and Keller (1995) show that 
negative (positive) framing may be more persuasive when the perceived efficacy of a solution is 
low (high).  In more recent work, Rasiel et al. (2005) use PT to rationalize risk-seeking behavior 
among terminally ill patients.  They suggest that patients’ reference points differ due to factors 
such as pre- and post-diagnosis life expectancies which therefore affect the chosen treatment 
paths.   
  Unlike traditional PT models, which have the reference point affecting the valuation of 
outcomes (Lenert et al., 1999; Treadwell and Lenert, 1999), we focus on how a patient’s 
reference point influences the subjective expectations of treatment success, thus determining the 
path of treatment, and impacting the perceived success of treatments after they have been 
pursued. 
 
A Prospect Theory Model of Treatment Choice 
Patients choose a treatment path if they expect it to have a positive impact on their current health 
status.  We assume that an individual’s expectations of post-treatment disease status depend on 6 
her subjective probabilities of treatment effectiveness, which in turn are influenced by her 
reference point.  The reference point for our purposes is the patient’s current status and the 
successfulness of her earlier treatments.  We assume there are three possible outcomes of 
treatment: the patient improves (b = “better”), the patient remains the same (0 = “no change”), 
and the patient worsens (w = “worse”). 
  These assumptions give us the following equation:  
). 0 ( ) ( ) ( ) ( ) ( ) ( ) , 0 ; , ; , ( v r w v q b v p r q w p b V π π π + + =              (2) 
The value v(b) is the value a patient places on feeling better relative to her current status, which 
occurs with objective probability p.  This is a gain in well-being, so v(b) is positive.  On the other 
hand, v(w) is the value placed on feeling worse relative to her current status, and occurs with 
probability q.  This is a loss in well-being and therefore v(w) is negative.  A third possibility is 
that the patient observes no change from her current situation with a resulting value of v(0), and 
probability r=1-p-q.   One might initially expect v(0) to equal 0, but values are affected by the 
reference value, and as a result v(0) could be negative if the current situation is relatively poor 
compared to earlier states, although v(0) would still exceed v(w).  We hypothesize that 
0≥v(0)>v(w) because a typical individual seeks medical treatment to improve her condition, 
contingent upon the outcomes of previous treatments.  We further maintain that losses are feared 
at least as much as gains are valued, so the absolute value of v(w) will equal or exceed that of 
v(b) given a one unit change in disease status. 
  The decision weights, ), (⋅ π  are the subjective probabilities of each outcome.  Thus (2) 
represents the individual’s subjective valuation of the treatment outcome.  As such, a negative 
(positive) overall value indicates that the individual perceives a negative (positive) valuation of 
pursuing further treatment.  A zero value indicates a perceived neutral valuation of receiving 7 
subsequent treatment.  To a large extent the final value will depend on the relative magnitudes of 
the decision weights.  For example, we know that if a patient anticipates an equal one unit 
change in disease status one way or the other (i.e. b = -w), if  ), ( ) ( q p π π ≤ and if v(0) = 0 or 
0 ) ( = r π , or both, the overall prospect valuation from (2) would be negative due to the absolute 
valuation of a loss being at least equal to that of a gain. 
  Assuming medical treatment is voluntary, all individuals agreeing to a treatment should 
have a positive subjective valuation at their reference point of the outcome; that is, 
. 0 ) 0 ( ) ( ) ( ) ( ) ( ) ( ) , 0 ; , ; , ( > + + = v r w v q b v p r q w p b V π π π   Assuming that v(0)=0 or π(r)=0 or both, 
this means  ( ) ( ) ( ) ( ) p v b q v w π π > − , or the subjective weighted gain from improving b units must 
exceed the subjective weighted loss from regressing w units.
5  Because v(w) is negative, the right 
hand side of the inequality is positive.  The inequality can then be rearranged to  
). ( / ) ( ) ( / ) ( b v w v q p − > π π                     (3) 
Equation 3 implies that a treatment is pursued only if the subjectively weighted probability of a 
gain relative to that of a loss exceeds the ratio of the (absolute) utility value of a loss divided by 
the utility value of a gain.  In terms of our specific application this has an interesting 
interpretation.  For any given values of v(w) and v(b), treatment is more likely to be pursued if 
there is only a relatively small subjective probability of the treatment leading to a worse 
outcome. 
  Acetazolamide is the drug generally viewed as the most effective form of treatment for 
IIH, and is usually the first treatment pursued.  Other medicinal options are generally reserved 
for patients who cannot tolerate acetazolamide.  If medication is ineffective, subsequent 
                                                 
5 Even though the model is conditioned on the assumption that v(0) = 0, it is a trivial extension to extend the results 
to the non-restricted case.  The math is available upon request from the authors.  Also, as we mentioned above, v(0) 
is most likely less than zero, otherwise treatment would not be sought.  This assumption essentially allows us to 
group v(0) and v(w) and analyze the probability of feeling better relative to not feeling better. 8 
treatment normally involves an invasive procedure such as neurosurgical shunts.  In Appendix A 
we discuss in more detail how the treatment path for IIH follows a specific sequence, but here, 
consider hypothetically two types of individuals, assuming all individuals place the same value 
on a one unit deviation from the reference point, regardless of what that point is.  Patient A is 
initially prescribed a medication of some sort; however, due either to its ineffectiveness or the 
individual’s inability to tolerate it, the patient is then given an invasive procedure.  Patient B on 
the other hand, for some reason moves directly to an invasive procedure.  Keeping in mind that 
treatment paths are being evaluated at a point in time after the previous treatment results have 
been observed, we expect that because they have different frames of reference due to different 
treatment paths, these two individuals will have different perceived valuations for the probability 
of success of the invasive procedure.  Given that A has already experienced a failed treatment we 
anticipate that person B would have a higher perceived probability ratio of success to failure.  
This implies the following: 
. )] ( / ) ( [ )] ( / ) ( [ A B q p q p π π π π >                      (4) 
  One testable hypothesis implied by (4) is that prior failed treatment makes it less likely 
that individuals will pursue subsequent treatment. Unfortunately we do not have the necessary 
data to test this hypothesis.  If, as the existing literature contends, expectations directly influence 
perceived treatment outcomes (Carver et al., 1994; Llewellyn-Thomas, Thiel, and McGreal, 
1992; Koller et al., 2000), an additional testable hypothesis implied by equation (4) is that patient 
A will be less likely to report an improvement in disease status from the invasive treatment, 
having already suffered a failure.  We do have the data to test the following hypothesis. 
 9 
Hypothesis 1: All else equal, a patient who has received more (fewer) failed treatments will be 
less (more) likely to report an improvement from the latest treatment. 
 
  In our application to IIH, hypothesis 1 suggests that among patients who received a 
medicinal prescription other than acetazolamide, those who had an initial unsuccessful 
experience with acetazolamide should be less likely to report an improvement in disease status 
than those who only had the alternative prescription.
6  Furthermore, among patients who 
eventually received an invasive procedure, those who received only the invasive procedure will 
be most likely to report an improvement, followed by patients who first had an alternative 
prescription, then individuals who were treated with acetazolamide before receiving the 
procedure, and finally patients who had both acetazolamide and an alternative prescription 
before receiving an invasive procedure.  The reason we expect patients who had acetazolamide 
prior to an invasive procedure to have a lower probability ratio than those who had an alternative 
prescription before a procedure is because acetazolamide is widely believed to be the most 
effective form of therapy for IIH.  We therefore expect patients who experienced a failure of this 
drug to be even less likely to anticipate an improvement from subsequent treatment.  To 
summarize: patients with fewer failed treatments will be more likely to report an improvement in 
the latest treatment than those having experienced more failed treatments. 
 
                                                 
6 In our application to IIH our ordering assumes that the acetazolamide was ineffective from its initial use.  If 
acetazolamide was at first effective and improving a patient’s condition, but over time lost its effectiveness, the 
ordering of anticipated probabilities may be opposite what we discuss here. 10 
Data 
Data for this study come from the Intracranial Hypertension Registry.
7  The Registry gathers 
information from individuals diagnosed with intracranial hypertension and their physicians.  
Patients are admitted to the Registry on a voluntary basis, however confirmatory data from at 
least one of the patient’s physicians is required for admission to the Registry. 
Because participation in the Registry is voluntary and either self or physician initiated, 
the patients in the Registry may not be representative of the entire population of IIH sufferers.  
At the time of this study the Registry contained information from 732 IIH patients.  This study 
focuses solely on patients in the Registry who reported a disease status relative to their pre-
diagnosis condition.  Individuals who did so rated their relative health status on a scale of 0 to 
10, 5 being “no change”.  Our primary variable of interest, better, is a binary variable created 
from this scale.  Patients who had a rating between 6 and 10 were given a value of 1, and based 
on the assumption that patients would most likely place a negative value on observing no change 
in their disease status, patients who claimed a status of “no change” or “worse” are grouped into 
a “not-better” category and coded as 0.  One hundred fifty-one observations remained after 
deleting missing values, the majority resulting from patients who did not report a post-treatment 
disease status.  Descriptions of the variables used in this study are contained in Table 1. 
Patient socioeconomic variables include real income earned from the last year worked 
(Earnings) and a collection of binary variables: whether the patient has health insurance 
(Health_Ins), whether the patient is working (Working), whether or not the patient is in a medical 
profession (MedDv), whether the patient has vision problems, (Vision), is obese (Obese), or 
                                                 
7 The registry is co-sponsored by the Intracranial Hypertension Research Foundation of Vancouver, Washington and 
the Casey Eye Institute at the Oregon Health and Science University (OHSU).  
http://www.ihrfoundation.org/news/registry.asp   11 
suffers from headaches (Headache).  Male and White are dummy variables indicating the gender 
and race of the patient.   
  Each patient was placed into one of 8 treatment categories.  AcetaRx indicates that the 
patient had been prescribed acetazolamide as well as an alternative medication.  AcetaInv and 
RxInv identify patients that received an invasive procedure in addition to acetazolamide or an 
alternative medication, respectively.  Invasive, Rx, and Aceta are all binary variables which equal 
one if the patient received only the given treatment.  AcetaRxInv indicates whether the patient 
received all three forms of treatment.  Patients who did not receive any of the above treatments 
serve as the base case.  A dummy variable was also created to identify patients who attempted 
weight reduction (Diet), because diets are often recommended by physicians due to the apparent 
link between obesity and IIH. 
Summary statistics for the sample and the Registry can be found in Table 2.  As shown 
by the t-test results in Table 2, the sample does not appear to be representative of all patients in 
the Registry.  Most mean values differ at p ≤ 0.10.  However, our sample does appear to be fairly 
representative of the population of all IIH patients, the statistics for which are also presented in 
Table 2.  We therefore argue that sample selection bias that may exist due to self-selection into 
this sample is likely to be relatively small.  Sixty-seven percent of the patients in our sample 
experienced vision problems, 85% suffered from headaches at some point, and 49% were obese 
at the time of diagnosis.  Roughly 93% of our sample is female and 92% is white. 
Forty-seven percent of our sample had attempted weight reduction (Diet), 9% had been 
prescribed only acetazolamide (Aceta), 5% had only been on an alternative form of medication 
(Rx), and 25% only received an invasive procedure (Invasive).  Five percent of our sample had 
been on both acetazolamide and an alternative prescription (AcetaRx), 21% had taken both of 12 
these and received an invasive procedure (AcetaRxInv), 14% had been on acetazolamide and 
received an invasive procedure (AcetaInv), while 17% had taken an alternative form of 
medication and had an invasive procedure (RxInv). 
 
Empirical Methods 
Our model implies that an individual pursues a subsequent treatment only if her ratio of the 
subjectively weighted probability of a gain relative to that of a loss exceeds the ratio of the 
(absolute) utility value of a loss divided by the utility value of a gain.  That, in turn, influences a 
patient’s probability of assessing a taken treatment as effective, leading to hypothesis 1 that 
patients with fewer failed treatments are more likely to report an improvement from their latest 
treatment.  The empirical results are conditioned on a point in time after treatment paths have 
been observed, so the treatment paths can be represented in the model by dummy variables.  Our 
dependent variable is the patient’s self-assessed post-treatment disease status.  Because this 
binary variable is created by imposing a chosen cutoff point on the 0-10 scale variable measuring 
the patient’s perceived health status,
8 there may be some miscoding, and thus misclassification, 
of the dependent variable.  That is, the variable measuring the patient’s true subjective outcome 
from the treatment is latent.  The relationship between the patient’s subjective outcome and the 
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8 See the discussion of the dependent variable in the Data section. 13 
where z is a vector of patient characteristics, including treatment history, T=1 implies that a 
given treatment was chosen, and R is the measured result.  R* represents the latent dependent 
variable denoting true subjective gains. 
Ordinarily a binary logistic or probit regression would be performed in this case to 
analyze the probability of a patient feeling better relative to not-better.  However, as mentioned 
above, one potential problem with this model is that the dependent variable is subject to 
misclassification error.  Failure to control for this when estimating a discrete-response model via 
traditional techniques such as Logit or Probit, can result in inconsistent estimates (Hausman et 
al., 1998).  Abrevaya and Hausman (1999) recommend using the semiparametric MRE as an 
alternative to parametric estimation.  Unlike the parametric approach, semiparametric estimation 
does not require that the mismeasurement be modeled correctly in order to obtain consistent 
estimates.  Therefore, the MRE is used to adjust for the potential misclassification bias.
9 
  For each model, we estimate the probability that a status of better occurs as a function of 
a linear index in the following patient characteristics and treatment variables: Male, White, 
Earnings, Health_Ins, Working, MedDv, Vision, Obese, Headache, Diet, Rx, Aceta, Invasive, 
AcetaRx, AcetaRxInv, RxInv, and AcetaInv.  
  To test hypothesis 1, the effects of the relevant treatment paths on the dependent variable 
are tested against each other.  A Wilcoxon signed-rank sum test, the nonparametric alternative to 
the paired t-test, is performed on the linear index β Xˆ  from two regressions, one where the two 
treatment variables being tested enter the regression separately and one where they are combined 
to form one variable.  This test consists of ranking the absolute differences between each pair of 
s ˆ β Xi  and calculating the Wilcoxon signed-rank statistic to test whether the median difference is 
                                                 
9 See Appendix B for a detailed discussion of the MRE.  Jason Abrevaya’s MRE code can be obtained at: 
http://www.krannert.purdue.edu/faculty/abrevaya/rankest.txt. 14 
zero.  If the restriction is valid, the sum of the ranks for the positive differences should 
approximately equal the sum of the ranks of the negative differences.  A rejection of the null 




ed Unrestrict β X β X ˆ ˆ
i i = , implies that the effects of 
the two treatment variables being tested are significantly different, and thus can be compared to 
one another. 
 
Results and Discussion 
Results from the MRE model can be viewed in Table 3.  Health insurance (Health_Ins) has a 
positive influence on disease status, and its estimate is the largest among all explanatory 
variables.  Patients in the medical profession (MedDv) and those who are obese are also 
significantly more likely to report an improvement in disease status.  The remaining significant 
patient characteristic variables, Male, White, Earnings, Working, Vision, and Diet, negatively 
affect the probability of better being reported by the patient. 
  In terms of the seven primary treatment variables, we are most interested in comparing 
the magnitudes of the effects that the previous treatments have on the probability that a patient 
claims a status of better relative to not better.
 10  Patients who received only acetazolamide 
(Aceta) show a highly significant increase in the probability of reported improvement.  This 
group has the largest coefficient estimate of all the treatment variables.  Individuals who had 
taken acetazolamide as well as a different medication (AcetaRx) have the second largest estimate, 
followed by those who only had an alternative medication (Rx), then patients who received 
acetazolamide as well as an invasive procedure (AcetaInv), those who only had an invasive 
procedure (Invasive) are next, then patients who received a medication other than acetazolamide 
                                                 
10 This is possible because all of these variables are binary and share the same omitted category. 15 
in addition to an invasive procedure (RxInv), and finally patients who received all three forms of 
treatment (AcetaRxInv).  All of these estimates are positive.  The expected and actual orderings 
of the treatment variables are displayed in Table 4. 
  Our primary hypothesis is that patients with unsuccessful prior treatments have a frame 
of reference leaving them less likely to expect improvement from subsequent treatments, and 
therefore less likely to report an improvement in disease status.  As shown in Table 4, our results 
indicate two failures out of six tests of this hypothesis: using acetazolamide prior to another 
treatment appears to increase a patient’s reported improvement from the subsequent treatment.  
That is, patients who had acetazolamide prior to receiving a different prescription are more likely 
to claim a status of better than those who only had the alternative medication.  The same is true 
of patients who had acetazolamide and an invasive procedure versus those who bypassed the 
medication and went straight to an invasive procedure.  As we noted earlier, this might indicate 
that for many of the patients acetazolamide was initially effective, giving them a frame of 
reference that the disease symptoms are treatable, but that they were unable to tolerate 
acetazolamide for an extended period of time due to its side effects (Wall, n.d.; IHRF, 2007c).  
The ordering suggested in equation 4 appears to hold for the remainder of the patients.  That is, 
patients who only had an invasive procedure are most likely to report an improvement, followed 
by patients who first had an alternative prescription, and finally, patients who had both 
acetazolamide and an alternative prescription before receiving an invasive procedure. 
  Except for the case of acetazolamide we have support for our primary hypothesis, and as 
explained, the failure of our hypothesis for the case of acetazolamide could be due to its 
outstanding effectiveness at reducing CSF within the skull (Gücer and Viernstein, 1978; Lubow 
and Kuhr, 1976; Rubin et al., 1966; Tomsak et al., 1988).  Further support for this conjecture 16 
comes from the fact that the treatment group consisting of patients who were only prescribed 
acetazolamide is by far the most likely to report an improvement in disease status.  The 
coefficient estimate for this group is over twice as large as the estimate for patients who in 
addition to having had acetazolamide were prescribed an alternative form of medication.   
  Two additional insights about the treatment of IIH come out of our analysis.  The first is 
that attempted weight reduction is the only form of treatment to decrease the probability that a 
patient would end up in the better category.  When considering how difficult dieting is for most 
people and the low success rate that exists among dieters, this result is not surprising.
11  Dieters 
tend to be frustrated with unsuccessful results, leaving them with lower expectations for the 
treatment’s effectiveness. 
  Perhaps our finding with the most important policy implications is that patients with 
health insurance are significantly more likely to perceive an improvement than those without it.  
This may be due to the fact that the nature of the disease leads physicians to treat symptoms 
rather than the root cause, which is expensive, and those with health insurance would be more 
likely to be able to afford an extensive set of treatments over an extended period of time.
12  
  Among the other variables in the model, higher earnings slightly decreases the 
probability of a better status, individuals with a history of vision problems and those who were 
working prior to IIH interfering with their daily life are also significantly less likely to report an 
improvement in post-treatment disease status, as are males and whites.  Patients in the medical 
profession and those who are obese are more likely to report an improvement.  The results 
discussed in this paragraph are difficult to explain; however, they may deserve further attention. 
 
                                                 
11 The long term success rate among all dieters is only 31%.  For females the success rate is only 27%. (Kruger et 
al., 2006). 
12 See Rosenman, et al. (2008) for a detailed discussion on the economic costs of IIH. 17 
Conclusions 
We provide a conceptual basis for how prior treatment failure or success along with other factors 
can influence a patient’s reference point that helps determine expectations and decisions on 
future treatment, empirically demonstrate support that a patient’s prior treatment failure or 
success may impact her perceptions about the effectiveness of subsequent treatments, and 
identify other factors that might influence patients’ reference points and perceptions.  The 
finding that prior treatment results affect the perceived success of subsequent treatments is 
important for physicians to know when prescribing additional treatment.  Physicians play a large 
role in providing information, and this knowledge would be very useful when prepping patients 
for whether or not the subsequent treatment will be effective.  The health insurance finding 
suggests that it may be especially important for patients diagnosed with idiopathic disorders 
where treatment is focused on symptoms to have good health insurance coverage if they are 
going to experience at least a perceived improvement in health status.  
  One of the primary shortcomings of our analysis is that our data come from a voluntary, 
self-reported registry.  While the data are likely to be quite accurate, they may not be 
representative of the population of IIH sufferers as a whole with respect to some variables.  
Based on the variables we were able to compare, our sample does appear to be fairly 
representative of the population of all IIH patients (see Table 2).  However, this potential 
registration bias may still limit some of our findings, particularly those associated with the race 
and gender of the patients.  Additionally, we are not able to explicitly control for the costs of IIH, 
which may influence the decision making process, nor does our study account for all other 
comorbidities that might occur because of IIH.  Finally, our data limitations require an empirical 
analysis that relies on indirect evidence.  Our empirical approach requires we assume that prior 18 
expectations of how successful a treatment will be are matched by ex post perceptions of 
treatment effectiveness.  A more direct test would utilize the implications from equation (4) and 
compare directly how prior unsuccessful (or successful, for that matter) treatment influences 
patients’ perceptions of expected success of subsequent treatment, and therefore, their propensity 
to have the treatment.19 
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Binary variable indicating patient's disease status.  Equals 1 if patient perceived 
themselves as better off than they were prior to diagnosis. 
Male  Binary sex variable, equals 1 if patient is male 
White  Binary race variable, equals 1 if patient is white_non Hispanic 
Earnings  Real income values from the last full year the individual worked. 
Working  Binary variable, equals 1 if patient was working the year prior to symptoms interfering 
with daily life 
Health_Ins  Binary variable, equals 1 if patient has health insurance 
MedDv  Binary variable indicating whether or not the patient has a background in health care 
Vision  Binary variable, equals 1 if patient suffered from problems with vision 
Obese  Binary variable, equals 1 if patient was obese at time of diagnosis 
Headache  Binary variable, equals 1 if patient suffered from headaches at any time 
Diet  Binary variable, equals 1 if patient attempted weight reduction 
Invasive  Binary variable, equals 1 if patient underwent a surgical procedure, including 
subsequent lumbar punctures, but was not on medication for IIH. 
Rx  Binary variable, equals 1 if patient was prescribed a medication for IIH other than 
acetazolamide, but did not receive acetazolamide, nor a surgical procedure 
Aceta  Binary variable, equals 1 if patient was prescribed acetazolamide, but did not receive 
additional medication for IIH, nor a surgical procedure 
RxInv  Binary variable, equals 1 if patient was prescribed a medication other than 
acetazolamide and underwent a surgical procedure, but did not receive acetazolamide.  
AcetaRxInv  Binary variable, equals 1 if patient was prescribed a medication other than 
acetazolamide in addition to acetazolamide, and underwent a surgical procedure. 
AcetaRx  Binary variable, equals 1 if patient was prescribed a medication other than 
acetazolamide in addition to acetazolamide, but did not undergo a surgical procedure. 
AcetaInv  Binary variable, equals 1 if patient was prescribed acetazolamide and underwent a 




  Sample  Registry 









* * * Malea   151  0.0662  0.2495  376.7493  732  0.1393  0.3465  248.6950 
* Whiteb   151  0.9205  0.2714  29.4799  732  0.8784  0.3270  37.2294 
Earnings  151  6425.6000  5216.2400  81.1791  152  6410.3100  5202.3500  81.1560 
Health_Ins  151  0.9205  0.2714  29.4799  194  0.9330  0.2507  26.8692 
Working  151  0.8278  0.3788  45.7588  176  0.8239  0.3820  46.3697 
MedDv  151  0.2252  0.4191  186.1214  196  0.2296  0.4216  183.6509 
* * * Visionc   151  0.6689  0.4722  70.5939  732  0.5246  0.4997  95.2623 
* * * Obesed   151  0.4901  0.5016  102.3463  732  0.1803  0.3847  213.3465 
* * * Headachee   151  0.8477  0.3605  42.5306  732  0.2910  0.4545  156.2035 
Diet***  151  0.4702  0.5008  106.5022  732  0.1708  0.3766  220.5140 
Rx  151  0.0464  0.2110  455.0667  732  0.0191  0.1371  716.6301 
Aceta**  151  0.0861  0.2814  326.8968  732  0.0355  0.1852  521.4498 
Invasive***  151  0.2517  0.4354  173.0176  732  0.4194  0.4938  117.7395 
AcetaRx  151  0.0464  0.2110  455.0667  732  0.0178  0.1322  744.1999 
AcetaRxInv***  151  0.2119  0.4100  193.4823  732  0.0724  0.2593  358.1738 
RxInv***  151  0.1656  0.3729  225.2465  732  0.0642  0.2453  382.0263 
AcetaInv***  151  0.1391  0.3472  249.6347  732  0.0560  0.2301  410.8128 
* implies Ho: Sample Mean = Registry Mean, rejected at significance level of 10%       
** implies Ho: Sample Mean = Registry Mean, rejected at significance level of 5%       
*** implies Ho: Sample Mean = Registry Mean, rejected at significance level of 1%       
a) Incidence of IIH for men is approximately .3/100,000, compared to 1/100,000 women (Binder et al., 2004). 
b) There is no evidence to suggest that race or ethnicity are significant determinants of IIH (Goodwin, 2006). 
c) Approximately 20% - 68% of all patients with IIH experience vision problems (Binder et al., 2004). 
d) Obesity is believed to be a risk factor for IIH, especially for women, with the incidence increasing from 1/100,000 to approximately 
19/100,000 for obese females between the ages of 20 – 44 (Binder et al., 2004; IHRF, 2007b). 




  Dependant Variable = Better 
Parameter  Estimate  95% Confidence Interval 
Intercept  ------  --------- 
  ------  --------- 
Male  -0.0881**  [-0.2250, -0.0250] 
  (0.0651)   
White  -0.1244**  [-0.2099, -0.0079] 
  (0.0595)   
Earnings  -5.1E-07**  [-6.82E-07, -5.1E-07] 
  (2.0473)   
Health_Ins  0.7468***  [0.4382, 0.8684] 
  (0.1354)   
Working  -0.0054**  [-0.0143, -0.0003] 
  (0.0044)   
MedDv  0.0045*  [-0.0010, 0.0072] 
  (0.025)   
Vision  -0.1259**  [-0.1749, -0.0273] 
  (0.0440)   
Obese  0.1011*  [-0.0005, 0.1997] 
  (0.0594)   
Headache  0.0634  [-0.0232, 0.1153] 
  (0.0415)   
Diet  -0.1194**  [-0.2457, -0.0305] 
  (0.0628)   
Rx  0.2063**  [0.0033, 0.2657] 
  (0.0845)   
Aceta  0.4918***  [0.3398, 0.7892] 
  (0.1311)   
Invasive  0.0598**  [0.0022, 0.0646] 
  (0.0199)   
AcetaRx  0.2801**  [0.0098, 0.3324] 
  (0.0989)   
AcetaRxInv  0.0250**  [0.0011, 0.0308] 
  (0.0094)   
RxInv  0.0411**  [0.0014, 0.0619] 
  (0.0206)   
AcetaInv  0.0766*  [-0.0104, 0.1037] 
  (0.0346)   
Standard errors are in parentheses.       
*Statistical Significance based on 90% confidence interval 
**Statistical Significance based on 95% confidence interval 










Rx > AcetaRx  <.0001  AcetaRx > Rx  Aceta  Aceta 
Invasive > RxInv  <.0001  Invasive > RxInv  Rx  AcetaRx 
Invasive > AcetaInv  <.0001  AcetaInv > Invasive  AcetaRx  Rx 
Invasive > AcetaRxInv  <.0001  Invasive > AcetaRxInv  Invasive  AcetaInv 
RxInv > AcetaRxInv  <.0001  RxInv > AcetaRxInv  RxInv  Invasive 
AcetaInv > AcetaRxInv  <.0001  AcetaInv > AcetaRxInv  AcetaInv  RxInv 
         AcetaRxInv  AcetaRxInv 
Note: p-values are for Wilcoxon signed rank sum test of the null hypothesis that the effects of the two treatment 
paths on the dependent variable are equal. 
 29 




Idiopathic Intracranial Hypertension 
Individuals afflicted with intracranial hypertension suffer from elevated cerebro-spinal fluid 
(CSF) pressure in the skull.  There are 2 types of intracranial hypertension (IHRF, 2007d).  The 
first is primary or idiopathic intracranial hypertension (IIH).  As the name implies, IIH arises 
spontaneously from an unknown cause.  The other is secondary intracranial hypertension, which 
is associated with, and usually a side effect of, an identifiable cause such as a different disease, 
an intracranial blood clot, or certain drugs (IHRF, 2007a).  The most common symptoms of 
increased intracranial pressure are headache and papilledema (Binder et al., 2004).  The latter is 
particularly problematic due to the fact that over time swelling of the optic disc can lead to 
blindness or irreversible deterioration of vision (Giovannini and Chrousos, 2005). 
Because the causes of secondary intracranial hypertension are known, its treatment can 
be tied to the patient’s primary condition, and thus treated relatively effectively even though the 
prevalence of the disease is unknown.  In this study we focus on IIH.  IIH is most common 
among women of child-bearing age and occurs at an approximate rate of 1/100,000 (Binder et 
al., 2004); roughly 3 times that of males.  Obesity is thought to be a risk factor for IIH, especially 
among women.  The rate increases approximately 19 fold for females between the ages of 20 – 
44 who are diagnosed as obese (Binder et al., 2004; IHRF, 2007b).  However, while gender is a 
significant determinant of IIH, there is little evidence to suggest that race or ethnicity are 
significantly correlated with IIH (Goodwin, 2006). 
There are several common treatments for idiopathic intracranial hypertension.  
Pharmaceutical treatments of IIH usually employ different types of diuretics, most commonly 
carbonic anhydrase inhibitors which reduce the production of CSF.  Medications of this type are 31 
the only ones known to be effective (Binder et al., 2004).  Acetazolamide (originally sold under 
the trade name Diamox) is the most common medication of this sort, and the primary drug used 
to treat IIH.  Its success in treating IIH has been well documented (Gücer and Viernstein, 1978; 
Lubow and Kuhr, 1976; Rubin et al., 1966; Tomsak et al., 1988).  Another diuretic that has been 
shown to lower intracranial pressure is furosemide (Lasix).  However, this drug does not appear 
to be as effective as acetazolamide, and in most cases is prescribed to individuals who cannot 
tolerate the latter (Binder et al., 2004; Gans, 2005).  Other medicinal options do exist; however, 
little, if any, clinical evidence exists to support their efficacy (Friedman, 2005). 
Due to the link between weight gain and IIH, physicians often recommend weight loss 
programs as a form of treatment.  Previous studies have shown that weight loss appears to be an 
effective treatment for IIH (Johnson et al., 1998; Kupersmith et al., 1998).  However, the 
importance of weight loss in this context remains unclear (Ball and Clarke, 2006; Binder et al., 
2004).  
Sugerman et al. (1995) report systematic improvement in patient symptoms following 
gastric bypass surgery
13.  Newborg (1974) documents resolution of papilledema in 9 patients 
after being treated with a diet alone.  However, the small sample size prevents these results from 
being generalized to the entire population afflicted with IIH. 
Surgical processes are generally reserved for patients who do not respond well to 
medicinal treatments.  There are 2 primary types of surgery that can be performed.  The first is 
optic nerve fenestration, where an incision is made in the sheath surrounding the optic nerve to 
relieve papilledema.  The second involves the use of neurosurgical shunts, which are used to 
drain the CSF into another area of the body (IHRF, 2007c).  The principle types of shunting 
                                                 
13 All of the patients in that study were on acetazolamide at one time, and it is unclear whether they continued to 
take the drug after surgery.   32 
procedures used to treat IIH are lumboperitoneal (LP) and ventriculoperitoneal (VP), although 
LP shunts are used most often as they are easier to insert (Binder et al., 2004; Friedman and 
Jacobson, 2004).  Revisions are quite common with both procedures.  LP shunts have a revision 
rate somewhere between 38% and 64% (Friedman and Jacobson, 2004).  VP shunts appear to 
have a slightly lower revision rate in the range of 23% to 41% (Bynke et al., 2004; Lund-
Johansen et al., 1994; Maher et al., 2001). 
  Repeated lumbar punctures are sometimes used as a surgical alternative.  However, 
according to Binder et al. (2004), this is a less than ideal approach to treating IIH and should 
only be used as an emergency measure for patients who experience a sudden loss of vision 
resulting from serious cases of papilledema.  Curry et al. (2005) maintain that the best surgical 
procedure for IIH remains unknown. 33 
Appendix B 
Monotone Rank Estimator (MRE) 
The following model is based on Abrevaya and Hausman (1999), and is an extension of Han’s 
(1987) generalized regression model.  The latent dependent variable is as follows: 
), , ( 0
* ε β x g R =                      (6) 
where ε is an i.i.d. error disturbance, and g is an unknown function containing strictly positive 
partial derivatives at every point.  The distribution of R then has the following c.d.f: 
), * | Pr( ) | ( * d R n R d n F R R = ≤ =                        (7) 
where n and d represent potential values for the dependent variable.  For a model with a binary 
dependent variable, the probabilities of misclassification are: 
) 0 * 1 Pr( 0 < = ≡ R R α                       (8) 
) 0 * 0 Pr( 1 > = ≡ R R α .                          (9) 
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  To estimate the parameters we use the MRE, which is a rank estimator for 
semiparametric monotonic linear index models.  The MRE consists of a vector 
MRE β ˆ  that 




MRE b x Rank R M b S ) ( ) ( ) (                    (12) 34 
over the set  }, 1 : { = ℜ ∈ ≡ l
l b b B  where ℜrepresents the real line, M is an increasing function 
in R,  β X'  is the linear index, l represents the number of covariates in x, and l b is the 
determinant of the b vector.  Two comments are in order here.  First, note that because the MRE 
is based on a rank-order process, there is no need to explicitly include an intercept in b xi .  
Second, equations (10) and (11) imply that the stochastic-dominance conditions are fulfilled 
when  1 0) 1 ( α α > − , which if it holds implies consistency of the parameter estimates.   
The Rank function is defined by: 
. ) ( ... 2 1 m b x Rank b x b x b x im in i i = ⇒ < < <               (13) 
Some examples of functions for M are given by Cavanagh and Sherman (1998).  For robustness, 
) ( ) ( R Rank R M = , for efficiency  R R M = ) ( , or an intermediate alternative would be 
}, { } { } { ) ( b R b b R a R a R a R M > + ≤ ≤ + < =  such that a and b are real numbers and a < b.  By 
using a semiparametric approach we may be sacrificing some efficiency relative to a correctly 
specified parametric model (Powell, 1994); therefore, we used the second option to increase the 
efficiency of our estimates.  Finally, the primary condition for consistency is that  ] ) ( [ E X R M  is 
a nonconstant increasing function of  ; 'β X  however, a sufficient condition for consistency is that 
the distribution of R for a higher R* first order stochastically dominates that of an R associated 
with a lower R*. 
 